Stock APLLTD ALEMBIC PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Alembic Pharmaceuticals Limited

Equities

APLLTD

INE901L01018

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 12:43:46 26/04/2024 BST 		5-day change 1st Jan Change
990.2 INR -0.73% Intraday chart for Alembic Pharmaceuticals Limited +5.53% +30.40%
04-18 Alembic Pharmaceuticals Board to Consider Dividend for Fiscal 2024; Shares Drop 3% MT
04-08 Alembic Pharmaceuticals Limited Received 3 Assessment Orders from the Office of Assistant Commissioner (ST), Andhra Pradesh CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 101,386 100,715 189,674 145,771 97,564 194,647 - -
Enterprise Value (EV) 1 108,614 117,382 190,614 152,248 103,100 197,263 194,189 191,167
P/E ratio 17.3 x 12.1 x 15.9 x 26.7 x 28.5 x 32.8 x 27.6 x 22.9 x
Yield 1.02% 1.31% 1.45% 1.35% 1.61% 0.9% 1.02% 1.13%
Capitalization / Revenue 2.58 x 2.19 x 3.52 x 2.75 x 1.73 x 3.07 x 2.77 x 2.5 x
EV / Revenue 2.76 x 2.55 x 3.53 x 2.87 x 1.82 x 3.11 x 2.76 x 2.46 x
EV / EBITDA 12.4 x 9.6 x 12.2 x 17.4 x 14.6 x 21.1 x 16.6 x 13.9 x
EV / FCF 68.7 x -52.5 x 23.7 x 120 x 36.8 x 45.9 x 38.2 x 31.4 x
FCF Yield 1.45% -1.9% 4.22% 0.83% 2.72% 2.18% 2.62% 3.18%
Price to Book 3.73 x 3.13 x 3.7 x 2.79 x 2.23 x 4.11 x 3.69 x 3.31 x
Nbr of stocks (in thousands) 188,520 188,516 196,563 196,563 196,563 196,563 - -
Reference price 2 537.8 534.2 965.0 741.6 496.4 990.2 990.2 990.2
Announcement Date 08/05/19 23/04/20 04/05/21 02/05/22 05/05/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 39,347 46,058 53,931 53,058 56,526 63,378 70,383 77,775
EBITDA 1 8,736 12,230 15,576 8,742 7,084 9,345 11,692 13,754
EBIT 1 7,584 10,657 13,741 5,874 4,329 6,581 8,660 10,475
Operating Margin 19.27% 23.14% 25.48% 11.07% 7.66% 10.38% 12.3% 13.47%
Earnings before Tax (EBT) 1 7,493 9,998 13,681 6,201 3,855 6,242 8,452 10,279
Net income 1 5,844 8,291 11,781 5,457 3,420 5,917 7,029 8,395
Net margin 14.85% 18% 21.84% 10.28% 6.05% 9.34% 9.99% 10.79%
EPS 2 31.00 43.98 60.81 27.76 17.40 30.22 35.93 43.16
Free Cash Flow 1 1,580 -2,235 8,039 1,267 2,805 4,300 5,088 6,084
FCF margin 4.02% -4.85% 14.91% 2.39% 4.96% 6.78% 7.23% 7.82%
FCF Conversion (EBITDA) 18.09% - 51.61% 14.5% 39.6% 46.01% 43.51% 44.24%
FCF Conversion (Net income) 27.04% - 68.23% 23.22% 82.03% 72.67% 72.38% 72.47%
Dividend per Share 2 5.500 7.000 14.00 10.00 8.000 8.888 10.06 11.15
Announcement Date 08/05/19 23/04/20 04/05/21 02/05/22 05/05/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 13,143 12,804 13,260 12,923 12,717 14,157 12,621 14,750 15,090 14,064 14,862 15,448 16,275 16,060
EBITDA 1 3,651 3,417 2,359 2,572 2,557 1,601 146.5 2,327 2,488 2,122 1,987 2,452 2,444 2,606
EBIT 3,181 - - - 1,997 370.2 - 1,650 1,822 1,381 - - 1,536 1,706
Operating Margin 24.2% - - - 15.7% 2.61% - 11.19% 12.08% 9.82% - - 9.44% 10.62%
Earnings before Tax (EBT) 1 3,183 2,919 1,826 2,002 1,967 405.9 -601.6 1,530 1,681 1,246 1,298 1,587 1,680 1,695
Net income 1 2,926 2,507 1,645 1,693 1,764 354.6 -658.8 1,334 1,219 1,526 1,206 1,470 1,413 1,467
Net margin 22.26% 19.58% 12.41% 13.1% 13.87% 2.5% -5.22% 9.04% 8.08% 10.85% 8.11% 9.51% 8.68% 9.14%
EPS 14.88 12.75 8.370 8.610 8.980 1.800 - 6.780 6.200 - - - 5.250 6.000
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 19/01/21 04/05/21 26/07/21 10/11/21 10/02/22 02/05/22 04/08/22 11/11/22 01/02/23 05/05/23 04/08/23 - - -
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 7,228 16,667 941 6,477 5,536 2,617 - -
Net Cash position 1 - - - - - - 457 3,479
Leverage (Debt/EBITDA) 0.8274 x 1.363 x 0.0604 x 0.7409 x 0.7815 x 0.28 x - -
Free Cash Flow 1 1,580 -2,235 8,039 1,267 2,805 4,300 5,088 6,084
ROE (net income / shareholders' equity) 23.7% 27.9% 28.2% 10.5% 7.12% 12.8% 14.2% 15.1%
ROA (Net income/ Total Assets) - - 18.6% 7.89% 5.14% - - -
Assets 1 - - 63,489 69,152 66,525 - - -
Book Value Per Share 2 144.0 171.0 261.0 266.0 222.0 241.0 268.0 300.0
Cash Flow per Share 2 43.10 23.80 75.50 27.60 36.80 42.80 45.00 40.40
Capex 1 6,539 6,726 6,595 4,256 4,434 3,297 3,058 3,327
Capex / Sales 16.62% 14.6% 12.23% 8.02% 7.84% 5.2% 4.35% 4.28%
Announcement Date 08/05/19 23/04/20 04/05/21 02/05/22 05/05/23 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Alembic Pharmaceuticals Limited

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
990.2 INR
Average target price
937.7 INR
Spread / Average Target
-5.31%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ALEMBIC PHARMACEUTICALS LIMITED Stock Alembic Pharmaceuticals Limited
+30.40% 2.33B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. APLLTD Stock
  4. Financials Alembic Pharmaceuticals Limited